Literature DB >> 21856167

Binding and activity of all human alpha interferon subtypes.

Thomas B Lavoie1, Eyal Kalie, Sara Crisafulli-Cabatu, Renne Abramovich, Gina DiGioia, Karlene Moolchan, Sidney Pestka, Gideon Schreiber.   

Abstract

Vertebrates have multiple genes encoding Type I interferons (IFN), for reasons that are not fully understood. The Type I IFN appear to bind to the same heterodimeric receptor and the subtypes have been shown to have different potencies in various experimental systems. To put this concept on a quantitative basis, we have determined the binding affinities and rate constants of 12 human Alpha-IFN subtypes to isolated interferon receptor chains 1 and 2. Alpha-IFNs bind IFNAR1 and IFNAR2 at affinities of 0.5-5 μM and 0.4-5 nM respectively (except for IFN-alpha1 - 220 nM). Additionally we have examined the biological activity of these molecules in several antiviral and antiproliferative models. Particularly for antiproliferative potency, the binding affinity and activity correlate. However, the EC50 values differ significantly (1.5 nM versus 0.1 nM for IFN-alpha2 in WISH versus OVCAR cells). For antiviral potency, there are several instances where the relationship appears to be more complicated than simple binding. These results will serve as a point of reference for further understanding of this multiple ligand/receptor system.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21856167     DOI: 10.1016/j.cyto.2011.07.019

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  82 in total

1.  Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes.

Authors:  Srilalitha Kuruganti; Shane Miersch; Ashlesha Deshpande; Jeffrey A Speir; Bethany D Harris; Jill M Schriewer; R Mark L Buller; Sachdev S Sidhu; Mark R Walter
Journal:  J Biol Chem       Date:  2015-11-06       Impact factor: 5.157

Review 2.  Impact of host genetic polymorphisms on vaccine induced antibody response.

Authors:  Janina E Linnik; Adrian Egli
Journal:  Hum Vaccin Immunother       Date:  2016-01-25       Impact factor: 3.452

3.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

4.  Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.

Authors:  Sebastian A Stifter; Antony Y Matthews; Niamh E Mangan; Ka Yee Fung; Alexander Drew; Michelle D Tate; Tatiana P Soares da Costa; Daniel Hampsey; Jemma Mayall; Phil M Hansbro; Albert Garcia Minambres; Sahar G Eid; Johnson Mak; Judy Scoble; George Lovrecz; Nicole A deWeerd; Paul J Hertzog
Journal:  J Biol Chem       Date:  2017-11-29       Impact factor: 5.157

5.  A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus.

Authors:  Peng Du; Lei Xu; Weiyi Qiu; Dadi Zeng; Junjie Yue; Shuang Wang; Peitang Huang; Zhiwei Sun
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 6.  Type I interferon signaling, regulation and gene stimulation in chronic virus infection.

Authors:  Sabelo Lukhele; Giselle M Boukhaled; David G Brooks
Journal:  Semin Immunol       Date:  2019-05-30       Impact factor: 11.130

Review 7.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

8.  Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.

Authors:  Marlena M Westcott; Jingfang Liu; Karishma Rajani; Ralph D'Agostino; Douglas S Lyles; Mercedes Porosnicu
Journal:  J Virol       Date:  2015-05-20       Impact factor: 5.103

9.  Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.

Authors:  Kham R Trinh; Alex Vasuthasawat; Kristopher K Steward; Reiko E Yamada; John M Timmerman; Sherie L Morrison
Journal:  J Immunother       Date:  2013-06       Impact factor: 4.456

Review 10.  IFN-α subtypes: distinct biological activities in anti-viral therapy.

Authors:  K Gibbert; J F Schlaak; D Yang; U Dittmer
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.